[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports]

Internist (Berl). 2018 Mar;59(3):282-287. doi: 10.1007/s00108-017-0316-y.
[Article in German]

Abstract

Two female patients were admitted due to ketoacidosis. Serum glucose was moderately elevated. The patients exhibited abdominal and neurologic symptoms. Treatment consisted of metformin, insulin glargin and empagliflozin, as well as glimepiride, insulin detemir and empagliflozin, respectively. Treatment with intravenous fluid replacement, insulin, glucose, potassium and buffer solution led to a normalisation of pH and serum glucose levels. Our report describes two cases of atypical ketoacidosis with moderately elevated serum glucose during sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy.

Keywords: Diabetes mellitus; Diabetic ketoacidosis; Fluid therapy; Insulins; Intensive care.

Publication types

  • Case Reports

MeSH terms

  • Benzhydryl Compounds / adverse effects*
  • Benzhydryl Compounds / therapeutic use
  • Blood Glucose / metabolism
  • Critical Care
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Therapy, Combination
  • Female
  • Fluid Therapy
  • Glucosides / adverse effects*
  • Glucosides / therapeutic use
  • Humans
  • Ketosis / blood
  • Ketosis / chemically induced*
  • Ketosis / diagnosis
  • Ketosis / therapy
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects*
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use

Substances

  • Benzhydryl Compounds
  • Blood Glucose
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin